Following the joint project started last march, DevsHealth incorporated its first spin-out 3CL-Bio, in cooperation with Fundació Lluita contra les infeccions and IrsiCaixa. The new company will serve as the vehicle to develop a new oral COVID-19 treatment.

BHV Partners, the first venture builder specialising in healthcare in Southern Europe, CataloniaBio & HealthTech member, has been granted €200,000 in a participatory loan from the National Innovation Company (Enisa) to consolidate its organisational structure and continue to project its international growth.

Genomcore (Made of Genes), leading company in data solutions for the implementation of precision medicine, has launched an investment round through Capital Cell, Europe’s first online investment platform specialized in biomedicine. The goal of the campaign is to reach €500,000 of funding to prepare the entry of a new strategic partner that will accompany the internationalization of the company, eventually concluding in the establishment of the company in the USA.

Omomyc (OMO-103) is a therapeutic mini-protein developed by Peptomyc SL, a spin-off company by the VHIO and Catalan Institute of Research and Advanced Studies’ (ICREA), which was co-founded by Laura Soucek in 2014. Having previously shown the preclinical efficacy and safety of this novel cell-penetrating mini-protein in mouse models, Laura Soucek’s team successfully developed anti-MYC peptides for the treatment of several tumor types, the first of which, OMO-103, now shows promise in becoming the first ever clinically viable and direct inhibitor of MYC – a protein implicated in driving and maintaining cancer.

Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company specialising in the treatment of Central Nervous System (CNS) disorders, and mjn-neuro, a start-up that designs, produces and sells medical devices, have announced the signing of a marketing agreement for mjn-SERAS, a wearable medical device that predicts the risk of suffering an epileptic crisis.

BME's acceleration programme has incorporated four new companies into its "Entorno Pre Mercado" (EpM) programme, which aims to accelerate the company's stock market debut. Onalabs, a member of CataloniaBio & HealthTech, is one of these four companies, along with Ludium, Vamos and V2C.

AbilityPharma, the biopharmaceutical company and CataloniaBio & HealthTech member, has been granted with €2 million of non-dilutive funding to speed up the regulatory path for its anticancer autophagy inducer ABTL0812.

DeepUll, CataloniaBio & HealthTech member, has raised €13 million in a Series B financing round. The medical diagnostics company is developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections.

ZeClinics has recently been awarded an EIC-Pathfinder Challenge by the European Innovation Council (EIC). Pathfinder are grants targeting specific strategic priorities with early-stage development of radically new technology and high-risk/high-gain breakthrough research. EdiGenT is one of the 8 selected projects over 132 eligible proposals in the strategic area of “Emerging technologies in cell and gene therapy”.

The Parc Taulí has obtained the license to manufacture customized health products in its facilities by the Generalitat de Catalunya. This license will allow the 3D Laboratory to manufacture in its facilities and supply to other hospital centers.  

A symposium, held in the framework of the PER-IADR in Marseille, has made a retrospective of the measures recommended in dentistry to protect against SARS-CoV-2 coronavirus infections, after more than two years of pandemic. Dentaid Research Center, members of CataloniaBio & HealthTech, stress the importance of establishing a protection protocol prior to the dental procedure, which includes mouth strips with highly effective antiseptics to control bacterial and viral infection during dental procedures.

Devicare, one of the leading biotechnology companies in urology in Spain, presents Canoxidin® to the market; a first-in-class oral treatment that will allow all Spanish urologists to reduce the risk of calcification of urological devices (bladder catheters, ureteral catheters or nephrostomy tubes) by up to 8 times according to the results of Torrecilla et al, 2020 published in BMC Urology.

Abzu, a CataloniaBio & HealthTech member, is one of 75 of Europe’s high-potential startups selected in the extremely competitive June cutoff of the 2022 European Innovation Council (EIC) Accelerator program.

Dr Marc Güell received the Ángela Ruiz Robles 2022 National Research Award for Young People, in the field of technology transfer, awarded by the Ministry of Science and Innovation of Spain.

These are data from the study "Strategic value chains in Catalan industry: analysis of dependencies and technological specialisation", by the Director of Economic Analysis of the Barcelona Chamber of Commerce, Carme Poveda. It is the 20th in the Papers collection of the Observatori de l'Indústria del Departament d'Empresa i Treball de la Generalitat.

A total of six Catalan companies are among the beneficiaries of PERTE in the section for cutting-edge health. The Ministry of Industry, Commerce and Tourism has published the provisional resolution of the PERTE with a total of 17 companies included in the list, of which six in Catalonia and three members of CataloniaBio & HealthTech: Biorem, Medichem and Vecmedical.

The venture capital, Invivo Capital, a member of CataloniaBio & HealthTech, has completed the sale of Versantis, the Swiss biotechnology company. In an agreement valued at 140 million euros, it is the second transaction in the HealthEquity portfolio, the firm's first vehicle. Last year they closed the transfer of Sanifit for 205 million to Vifor Pharma, which was the largest operation in the biotechnology sector in Spain.

Affirma Biotech, CataloniaBio & HealthTech member, announced today the closing of its seed capital round with a total of 600,000 euros that the company will invest in the optimization of its preclinical candidates. During the past year a total amount of 960.000 euros in funding has been raised by the company from several business angels with extensive experience in the biotech industry. The lead investors of this round are Alfons Hidalgo (founder of Infinitec), Luis Ruiz Avila and Reig Jofre Investments, among others. Affirma Biotech also has Start-up Capital aid, granted by Acció. 

Tailor Surgery is the new spin-off of the Parc Taulí Research and Innovation Institute (I3PT), a CataloniaBio & HealthTech member, which is formed with the aim of globally marketing the line of customized instruments and customized implants in traumatology of the 3D Laboratory of the Institute.

La gestora de capital risc Asabys ha anunciat el llançament d’un nou fons, Sabadell Asabys Health Innovation Investments II (SAHII 2), per continuar invertint en innovació tecnològica en salut i consolidar la seva posició com a firma de capital privat líder en aquest àmbit al sud d’Europa.